What “MSN Safinamide patent” usually refers to
Safinamide (brand name includes Xadago) is an established medicine for Parkinson’s disease, and “MSN Safinamide patent” typically refers to patent rights held by, or connected to, MSN Laboratories and/or filings around safinamide’s manufacture, formulation, or method of use. The term “MSN” is commonly used in patent documents and generic-market discussions to identify the company’s role in a particular case or filing, but the exact patents depend on the country and the application/portfolio being discussed.
To answer precisely (which patent(s), where, and the expiry), the missing piece is the jurisdiction and the exact patent/application number (or the court/document you saw).
How to identify the right safinamide patents (and expiry) for MSN
Safinamide patent questions almost always turn on one of these categories, each with different expiry and exclusivity timelines:
- Drug substance (active ingredient) patents: often expire years after the earliest filing.
- Formulation patents: can extend protection if they cover a specific formulation or delivery approach.
- Method-of-use patents: cover particular dosing regimens or therapeutic claims.
- Regulatory exclusivity / data exclusivity: depends on the country’s drug-regulation system (sometimes extending beyond the core patent).
If you tell me the country (e.g., India, US, EU, UK) and what you’re looking at (label, patent number, or a link), I can map the likely relevant safinamide patent family and what tends to control generics entry there.
When would a safinamide generic be able to launch? (the practical test)
For “when can generic safinamide enter,” the controlling factors are usually:
- the last expiring patent protecting the relevant claim (substance/formulation/method), and
- any regulatory exclusivity that blocks approval or marketing in that jurisdiction.
People commonly search this because they want to know whether a specific company (often the one behind the “MSN” reference) can sell a generic immediately or whether they must wait for patent expiry or resolve litigation.
Why “MSN” might come up in safinamide patent searches
Company names tend to appear in patent landscapes and generic entries for three common reasons:
- A company filed a generic application that triggers patent listing or challenges.
- A company is named in patent disputes (in some systems, generics must address listed patents).
- A company holds or licenses a particular formulation/method patent that is still in force.
The exact reason depends on the case and jurisdiction.
What I need from you to give the exact patent answer
Send any one of the following and I’ll respond with the specific patent(s), numbers, holders, and likely expiry/entry implications:
- the country you mean by “MSN safinamide patent”
- a patent/application number you saw
- a link to the patent listing or notice
- the context (e.g., “for generic entry,” “for litigation,” “expiry date,” “which MSN company”)
Common next searches (if you’re doing a market/generic check)
People often follow up with:
- “When does Xadago (safinamide) patent expire in [country]?”
- “Which safinamide patents block generic entry in [country]?”
- “Is MSN challenging the patent or is MSN the patent holder?”
- “Do formulation or method-of-use patents extend protection past the API patent?”
If you reply with the jurisdiction (India/US/EU/UK/etc.), I can narrow this to the relevant safinamide patent families tied to MSN and give a concrete expiry-focused answer.